drugset

drugset / Trial / NCT02636725

Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas

NCT02636725 ↗

Phase 2 Completed 33 enrolled Jonathan Trent, MD, PhD Merck Sharp & Dohme LLC · collab Pfizer · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this research study is to test if Axitinib together with Pembrolizumab can slow tumor growth and know the side effects of the combination treatment.

Timeline

Start: 2016-04-19
Primary completion: 2018-05-08
Completion: 2023-03-03

Publications

Results Wilky BA, Trucco MM, Subhawong TK, Florou V, Park W, Kwon D, Wieder ED, Kolonias D, Rosenberg AE, Kerr DA, Sfakianaki E, Foley M, Merchan JR, Komanduri KV, Trent JC. Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial. Lancet Oncol. 2019 Jun;20(6):837-848. doi: 10.1016/S1470-2045(19)30153-6. Epub 2019 May 8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Axitinib	Small molecule	2 mg	Oral
Subject	Axitinib	Small molecule	5 mg	Oral
Subject	Axitinib	Small molecule	10 mg	Oral
Subject	Pembrolizumab	Monoclonal antibody	200 mg	Intravenous

Indications